编号：2025-026 | 投资者关系活动 | □特定对象调研□分析师会议 | | | | | --- | --- | --- | --- | --- | | 类别 | □媒体采访√业绩说明会 | | | | | | | □新闻发布会□路演活动 | | | | | □现场参观 | | | | | | □其他（请文字说明其他活动内容） | | | | | 参与单位名称及 | 投资者网上提问 | | | | | 人员姓名 | | | | | | 时间 | | | 2025 年 6 月 12 日 (周四) 下午 14:30~16:50 | | | 地点 | | | | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | | | | 上市公司接待人 | 1、财务总监易廷浩 | | | | | 员姓名 | 2、董事会秘书高健 | | | | | | 投资者提出的问题及公司回复情况 | | | | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | | | | 1、公司目前现金充足，是否考虑择机进行股份回购？ | | | | ...

【今日头条】 宁德时代(03750)公布H股发售价：厘定为每股H股263.00港元 宁德时代在港交所公告称，发售价已于2025年5月15日厘定为每股H股263.00港元。发售量调整权已获悉 数行使，据此，本公司将按发售价发行及配发17,684,100股额外发售股份，占全球发售项下初步可供认 购的发售股份总数的约15.0%。根据发售量调整权发行及配发的额外发售股份将根据香港公开发售与国 际发售之间的初始比例7.5%，92.5%予以分配。 假设全球发售于2025年5月20日上午八时正或之前成为无条件，预期H股将于2025年5月20日上午九时正 在联交所主板开始买卖。H股将以每手买卖单位100股H股买卖。 【大势展望】 穆迪将美国信用评级由AAA下调至AA1 上周末美股截至收盘，道指涨331.99点，涨幅为0.78%，报42654.74点；纳指涨98.78点，涨幅为0.52%， 报19211.10点；标普500指数涨41.45点，涨幅为0.70%，报5958.38点。标普500指数为连续第五个交易日 上涨。大型科技股多数上涨，特斯拉涨超2%，奈飞、谷歌涨超1%。 热门中概股多数上涨，纳斯达克中国金龙指数收涨0.52 ...

Core Insights - The core viewpoint of the news is that Hendi Pharmaceutical experienced significant declines in revenue and profit in 2024, primarily due to reduced sales of its core product, ibuprofen raw materials, and low international market prices [2][4] Financial Performance - In 2024, Hendi Pharmaceutical achieved operating revenue of 445 million yuan, a year-on-year decrease of 32.75% [2] - The net profit attributable to shareholders was 91.54 million yuan, down 48.02% year-on-year [2] - The net profit after deducting non-recurring gains and losses was 72.95 million yuan, a decline of 57.14% year-on-year [2] - Basic earnings per share were 0.32 yuan [2] Revenue Breakdown - The decline in operating revenue was mainly due to a decrease in sales volume of ibuprofen raw materials and low international market prices [4] - The raw materials segment generated revenue of 356 million yuan, accounting for 79.88% of total revenue [4] - The formulation segment contributed 85 million yuan, representing 19.11% of total revenue [4] Product Performance - Revenue from non-steroidal anti-inflammatory drugs (ibuprofen) was 317 million yuan, down 40.69% year-on-year, making up 71.15% of total revenue [4] - The cardiovascular segment saw revenue of 63.49 million yuan, a slight increase of 1.10% year-on-year, with stable performance from products like Torasemide tablets [4] R&D and Future Plans - R&D investment in 2024 was 32.94 million yuan, a decrease of 37.59% year-on-year, with the R&D expense ratio dropping to 7.39% [4] - The company added one new Chinese invention patent and several products entered the technical review stage [4] - The high-end pharmaceutical formulation internationalization project has been postponed to 2026, focusing on the coordinated development of raw materials and formulations [4]